Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019070 · ClinicalTrials.gov registry record · Phase 1
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01019070 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28 participants.
The verdict
NCT01019070, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
Interventions
- DRUG BMS-650032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019070
The ClinicalTrials.gov registry entry for NCT01019070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-650032 is the first listed.
NCT01019070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01019070 about?
NCT01019070 is a clinical study titled "Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032". The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
What is the current status of trial NCT01019070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01019070?
The interventions under investigation include: BMS-650032 (DRUG).
Who is sponsoring clinical trial NCT01019070?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.